Garen G. Bohlin, Director at Karyopharm Therapeutics Inc. (KPTI), bought 4,000 shares at $7.82 ($31K) on 2021-05-06, disclosed to the SEC on 2021-05-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| KPTI | BUY | 2023-09-12 | $100K | — | Filing → |